The in vitro susceptibilities of 63 isolates of Stomatococcus mucilaginosus and of 188 isolates of Micrococcus spp. to 18 antimicrobial agents were determined by the agar dilution method. Many ␤-lactams, imipenem, rifampin, and the glycopeptides were shown to be active in vitro against Stomatococcus and Micrococcus isolates, whereas the activities of antibiotics such as some aminoglycosides, erythromycin, and fosfomycin against an important number of these microorganisms are limited.
The predominant class of microorganisms causing bacteremia, especially in neutropenic patients, has changed over the past 15 years from aerobic gram-negative bacilli to gram-positive cocci. Although Staphylococcus aureus remains the most commonly isolated agent, the list of gram-positive pathogens now includes a growing number of commensal bacteria: coagulase-negative staphylococci, viridans group streptococci, and, most recently, Stomatococcus mucilaginosus and Micrococcus spp.; both genera are members of the family Micrococcaceae (12, 13, 16) . S. mucilaginosus is considered part of the normal flora of the human mouth and the upper respiratory tract (3) . Though it appears to be an organism of low virulence, the recent increase in the number of reported cases of S. mucilaginosus bacteremia has established the pathogenic potential of this organism. The most frequent clinical presentations include septicemia, endocarditis, and catheter-related sepsis (2, 8, 9, 12, 13, 15) . Micrococcus spp. are found as normal inhabitants of human skin and mucous membranes and are usually disregarded as contaminants in clinical isolates (6) . Nevertheless, strains identified as Micrococcus spp. have been involved as causative organisms in septicemia, endocarditis, central nervous system infection, peritonitis, and pneumonia (1, 10, 12, 18) .
Previous studies have examined the susceptibilities either of single isolates or of a strain collection against selected compounds only (5, 12, 13, 17) . However, data on susceptibility patterns of a large number of isolates against a panel of antimicrobial agents are so far not available. Therefore, we tested the in vitro activities of a representative number of commonly used antibiotics against 63 isolates of S. mucilaginosus and against 188 isolates of micrococci.
Bacterial strains. S. mucilaginosus was isolated from the mucous membrane of the cheek and gingiva; Micrococcus spp. were isolated additionally from the skin. A total of 36 isolates of S. mucilaginosus and 104 isolates of micrococci were obtained from swabs of 50 healthy persons; a total of 27 isolates of S. mucilaginosus and 84 isolates of micrococci were obtained from swabs of 50 neutropenic patients. At the time of specimen isolation, patients did not reveal any clinical signs of infections and had not been treated previously with antibiotics for at least 7 days.
Isolates of S. mucilaginosus were identified on the basis of the following characteristics: the presence of gram-positive cocci in clusters; strong adherence of the usually mucoid, transparent, or whitish organisms to the agar surface; weakly positive or negative catalase reactivity; and the inability of the organisms to grow on nutrient agar containing 5% NaCl. When heart infusion broth was used as a basal medium, the isolates hydrolyzed esculin and produced acid from glucose, fructose, sucrose, trehalose, and mannose (3, 16) . Identification as Micrococcus spp. was based on typical Gram stain morphology with large gram-positive cocci in tetrads and irregular clusters and aerobic growth of catalase-positive, usually circular, entire, convex, and smooth colonies on furazolidone agar. In biochemical testing, production of acid was weak and limited to a few sugars. In the API-Staph system (API System, La Balme les Grottes, France), typical profiles were 0004006 and 0000005 (Micrococcus spp.). For additional differentiation of Staphylococcus spp., resistance to lysostaphin (Lysostaphin Test; Hoffmann-La Roche, Grenzach-Wyhlen, Federal Republic of Germany [FRG]) was employed (7) . Micrococcus spp. were identified only to genus level by the conventional method, since attempts at further species identification by means of the simple biochemical tests performed in a routine clinical laboratory are mostly inconclusive (7, 11, 16) .
Susceptibility testing. The MICs were determined by the standard agar dilution method (14) . Mueller-Hinton agar (Difco, Augsburg, FRG), supplemented with 5% sheep blood was used for both S. mucilaginosus and Micrococcus spp. A 1:100 dilution of a fresh overnight culture was applied to agar plates by using a multipoint inoculator (Mast Laboratories Ltd., Bootle, England), yielding a final inoculum of 10 4 CFU per spot. The results were read after 18 h of incubation at 37ЊC. The isolates of S. mucilaginosus were incubated in 6% CO 2 . Sterility and growth controls, as well as activity controls using reference strains, were always performed. The MIC of each antibiotic was defined as the lowest concentration which inhibited visible growth of the organism.
Compounds. The following 18 antimicrobial agents in the form of standard powders of known potency for laboratory use were supplied by the indicated manufacturers: penicillin (Grün-enthal, Stolberg, FRG), ampicillin (Hoechst, Frankfurt, FRG), cefazolin (Eli Lilly, Giessen, FRG), cefotiam (Takeda, Aachen, FRG), cefuroxime (Hoechst), cefotaxime (Hoechst), imipenem-cilastatin (MSD, Munich, FRG), gentamicin (Merck, Darmstadt, FRG), amikacin (Bristol-Myers Squibb, Munich, FRG), netilmicin (Essex Pharma, Munich, FRG), erythromy-cin (Abbott, Wiesbaden, FRG), clarithromycin (Abbott), clindamycin (Upjohn, Heppenheim, FRG), vancomycin (Eli Lilly), teicoplanin (Marion Merrell Dow, Rüsselsheim, FRG), rifampin (Grünenthal), fosfomycin (Boehringer, Mannheim, FRG), and fusidic acid (Thomae, Biberach an der Riss, FRG). These agents were dissolved in appropriate solvents to prepare stock solutions and were then diluted in water and added to molten supplemented Mueller-Hinton agar to provide a final range of twofold concentrations from 0.031 to 16 g/ml when tested.
S. mucilaginosus. The MIC ranges and the MICs at which 50% (MIC 50 s) and 90% (MIC 90 s) of the 63 strains of S. mucilaginosus are inhibited are shown in Table 1 . Among the ␤-lactam antibiotics tested, ampicillin was the most active compound in vitro (MIC 90 , Յ0.031 g/ml). The activity of penicillin was similar to that of imipenem, with MIC 90 s of Յ0.125 g/ml. Among the cephalosporins tested, cefotaxime was most active (MIC 90 , 0.063 g/ml). Several strains were inhibited only by high concentrations of cefazolin and cefotiam. Compared to ␤-lactam antibiotics, aminoglycosides, particularly netilmicin (MIC 90 , Ͼ16 g/ml) and amikacin (MIC 90 , 8 g/ ml), were clearly less active, with elevated MICs for many isolates. Among the macrolides tested, erythromycin was less active than clarithromycin (MIC 90 s, 1 and Յ0.031 g/ml, respectively). The MIC 90 of clindamycin for S. mucilaginosus was 2 g/ml. The activity of teicoplanin against S. mucilaginosus was slightly higher than that of vancomycin, the other glycopeptide tested (MIC 90 s, 0.5 and 1 g/ml), and comparable to the activity of fusidic acid. Rifampin was the most active compound. All strains of S. mucilaginosus were inhibited by a concentration of Յ0.031 g/ml. Of the 63 strains tested, 17 were not inhibited by concentrations of Ͻ16 g of fosfomycin per ml.
When data were analyzed with regard to the origins of the isolates, i.e., neutropenic patients versus healthy persons, careful comparisons of the MIC ranges, MIC 50 s, and MIC 90 s yielded similar results among the subgroups, with the MIC 50 s and MIC 90 s being identical for most antimicrobial agents or differing by at most one dilution step. These differences were detectable particularly for aminoglycosides, with isolates from patients being slightly less susceptible than isolates from volunteers (data not shown).
Micrococcus spp. The ranges of MICs, the MIC 50 s, and the MIC 90 s for the 188 strains of Micrococcus spp. tested are shown in Table 2 . Among the ␤-lactam antibiotics tested, penicillin and imipenem were most active against micrococci (MIC 90 , 0.125 g/ml). The in vitro activities of the four cephalosporins tested were similar (MIC 90 s, 1 g of cefotiam, cefuroxime, and cefotaxime per ml and 2 g of cefazolin per ml). Single strains which required elevated cefazolin, cefotiam, and cefuroxime MICs were observed. Similarly, a number of isolates were not inhibited even in the presence of high aminoglycoside concentrations. Gentamicin (MIC 90 , 1 g/ml) was more active than amikacin or netilmicin, with MICs for the majority of strains being two dilutions lower than those of amikacin or netilmicin. Among the macrolides tested, erythromycin was again less active than clarithromycin (MIC 90 , Ͼ16 and 1 g/ml, respectively). The MICs of clindamycin for micrococci were comparable to those of ampicillin (MIC 90 , 0.25 g/ml). No differences in susceptibility regarding the activities of the glycopeptides against micrococci (MIC 90 , 1 g/ml) were found. Again, rifampin was the most active compound among the agents tested. All strains of micrococci except one were inhibited by a concentration of Յ0.031 g/ml. Fosfomycin showed limited activity against many strains: the MIC 50 was higher than 16 g/ml. Similarly, the activity of fusidic acid against micrococci was low, yet with a larger proportion of moderately susceptible strains (MIC 90 , 4 g/ml). Comparison of the patient and volunteer subgroups yielded similar results (data not shown).
Our study presents for the first time a thorough evaluation of MICs of a representative panel of antimicrobial agents against a large number of S. mucilaginosus and Micrococcus isolates obtained both from volunteers and from patients at risk for invasive infection.
The results concerning the antimicrobial susceptibilities of our strains were generally in agreement with those reported by other investigators. Nearly all S. mucilaginosus strains described in the present communication as well as clinical isolates of S. mucilaginosus reported in the literature were susceptible (8, 13) , and the glycopeptides (2, 9, 12, 13); however, isolates revealing diminished susceptibility or resistance to penicillin have been described (2, 8, 13, 15) . Some of these strains were implicated in serious infections such as endocarditis (15) and septicemia (2, 13) . Our data, as well as the results reported by other investigators (5, 9, 13, 17), show that low-level resistance towards aminoglycosides is a common feature of S. mucilaginosus. Among the macrolides tested, clarithromycin was more active than erythromycin, with MICs for the majority of strains being at least two dilutions less than those of erythromycin. Concerning erythromycin, limited in vitro activity towards S. mucilaginosus is reported (2, 4, 17) .
Regarding Micrococcus spp., data on susceptibilities are rare. Strains recovered from clinical sources were susceptible to most antibiotics (10, 12, 18) ; however, clinical isolates resistant to penicillin and to erythromycin have been reported (1, 12) . This has been confirmed by our results, in which we found strains that required elevated penicillin and erythromycin MICs as well. Additionally, we observed a large number of strains that required elevated MICs of fosfomycin and of the aminoglycosides.
In conclusion, our study demonstrates that many ␤-lactams, imipenem, rifampin, and the glycopeptides show increased in vitro activity against Stomatococcus and Micrococcus isolates, whereas activities of antibiotics such as some aminoglycosides, erythromycin, and fosfomycin against an important number of these microorganisms are limited. For the first time, these findings may provide a basis for studies evaluating in vitro synergism, animal infection models, and future clinical trials.
